Women getting abortions without ever setting foot in Louisiana
In a moment that reveals how fragile access to medical care can become amid shifting legal tides, the Supreme Court quietly intervened to preserve the ability of women across the United States to receive mifepristone by mail, setting aside a lower court order that would have required in-person dispensing. The unsigned order, offered without explanation, is not a resolution but a pause — a temporary shelter while courts continue to wrestle with whether the FDA's 2023 policy permitting telehealth prescriptions and mail delivery can endure legal challenge. At stake is not merely a pill, but the architecture of abortion access for millions of women, particularly those in rural communities and states where clinics have all but disappeared.
- A lower court's sudden order requiring in-person dispensing of mifepristone threatened to immediately cut off time-sensitive care for women who depend on telehealth and mail delivery — with no warning and no alternative in place.
- Drug manufacturers warned of cascading chaos: supply chains disrupted, pharmacies and clinicians left legally confused, and vulnerable patients — rural, caregiving, working — facing barriers they could not quickly overcome.
- The Supreme Court's unsigned order stepped in without explanation, blocking the restriction and preserving mail access while litigation continues, but offering no signal about how the deeper legal battle will ultimately be resolved.
- Justices Alito and Thomas dissented sharply, with Thomas invoking an 1873 law to call mifepristone distribution a criminal enterprise and Alito framing the ruling as an affront to the Dobbs decision that returned abortion law to the states.
- The case now returns to lower courts as the Trump administration accelerates a safety review of mifepristone, leaving the future of medication abortion — which accounts for 65 percent of all clinician-provided abortions in the U.S. — genuinely uncertain.
On a Thursday in May, the Supreme Court moved quietly but consequentially, issuing an unsigned order to preserve mail access to mifepristone after a lower court had abruptly required the abortion pill to be dispensed only in person. No explanation accompanied the decision — just the effect: women could continue receiving the drug through telehealth consultations and home delivery while the legal fight over its availability pressed on.
The case originates with Louisiana, a state that has effectively banned abortion except in narrow circumstances. Louisiana challenged the FDA's 2023 decision to loosen restrictions on mifepristone, arguing the pill was enabling thousands of unlawful abortions annually by crossing state lines. Officials said they had spent over $17,000 investigating out-of-state providers and that medication abortions had surged since Roe v. Wade was overturned in 2022.
The two pharmaceutical companies that manufacture mifepristone warned the Court that the appellate ruling had created immediate disruption — patients in rural areas, those without transportation, those managing childcare or work, all suddenly cut off from time-sensitive care. The FDA itself declined to take a position before the justices.
The stakes are significant: in 2023, medication abortion accounted for 65 percent of all clinician-provided abortions in the United States, with more than 1.1 million procedures that year. The pill has become the primary means of abortion access for women who cannot or will not travel to a clinic.
Two justices dissented. Clarence Thomas invoked the Comstock Act of 1873 to characterize mifepristone distribution as a criminal enterprise. Samuel Alito argued that continued access in states like Louisiana had undermined the Dobbs ruling's intent to return abortion regulation to the states.
The Court's intervention is temporary. A federal district court had already paused Louisiana's original lawsuit while the FDA conducts a safety review, which the Trump administration has signaled it will complete on an accelerated timeline. The fundamental legal question — whether remote prescribing and mail delivery of mifepristone can survive challenge — remains unanswered. For now, access holds. But only for now.
On Thursday, the Supreme Court stepped in to preserve something that had suddenly become precarious: the ability of women across the country to receive an abortion pill by mail. A lower court had just blocked that option, requiring instead that mifepristone be dispensed only in person. The high court's unsigned order, with no explanation attached, set that restriction aside—at least for now—ensuring that patients could continue obtaining the drug through telehealth consultations and having it shipped to their homes while the legal fight over its availability continues.
The case traces back to Louisiana's challenge to the Food and Drug Administration's 2023 decision to loosen restrictions on mifepristone. The state, which has effectively banned abortion except in narrow circumstances, argued that the pill was flooding across its borders, enabling what it called thousands of unlawful abortions annually. Louisiana officials said they had spent more than $17,000 investigating out-of-state providers shipping the drug into the state and that medication abortions had skyrocketed since the Supreme Court overturned Roe v. Wade in 2022. The state wanted the old rule back—the one requiring women to pick up the pill in a clinic, in person.
Two pharmaceutical companies that make mifepristone, Danco Laboratories and GenBioPro, had warned the Supreme Court that the appellate court's decision created immediate chaos. Patients in rural areas, those without reliable transportation, those juggling childcare or work schedules—all faced sudden barriers to time-sensitive medical care. The companies said the disruption threatened supply chains and left clinicians and pharmacies confused about what they could legally do. The FDA itself did not take a position on the matter before the justices.
The numbers underscore why this fight matters. In 2023, medication abortion accounted for 65 percent of all clinician-provided abortions in the United States. More than 1.1 million abortions were provided by health care workers that year, including those delivered by telehealth to patients in states where abortion is heavily restricted. The pill—mifepristone, taken with a second drug called misoprostol—has become central to abortion access in America, especially for women who cannot or will not travel to a clinic.
Two justices dissented. Samuel Alito and Clarence Thomas argued that the drug manufacturers had not shown they would suffer irreparable harm if the appellate court's order stood. Thomas invoked the Comstock Act, an 1873 law banning the mailing of abortion-related drugs, calling the companies' profits from mifepristone a "criminal enterprise." Alito went further, writing that the continued availability of the pill in states like Louisiana had "thwarted" state officials' efforts to largely eliminate abortion. He framed the case as an attempt to undermine the Dobbs decision that returned abortion regulation to the states.
The legal landscape remains unsettled. A federal district court had paused Louisiana's original lawsuit against the FDA in April while the agency conducts a safety review of mifepristone. The Trump administration has indicated it plans to complete that review faster than the typical year-long timeline. Meanwhile, the case will return to lower courts, where the fundamental question persists: whether the FDA's decision to allow remote prescribing and mail delivery of mifepristone can survive legal challenge. For now, women nationwide can still obtain the pill by mail. But the Supreme Court's intervention is temporary, a holding action while the deeper fight plays out.
Notable Quotes
Patients and clinicians have relied on dispensing mifepristone without an in-clinic visit for years, particularly for women from rural areas and those for whom transportation, childcare, or occupational constraints make it difficult to see providers in person.— GenBioPro, a manufacturer of mifepristone
The continued availability of mifepristone in states like Louisiana has thwarted state officials' efforts to largely ban abortion.— Justice Samuel Alito, dissenting
The Hearth Conversation Another angle on the story
Why did Louisiana bring this lawsuit in the first place? What was the state actually trying to accomplish?
Louisiana wanted to reclaim control over abortion within its borders. The state has essentially banned the procedure, but mifepristone was arriving by mail from out-of-state providers, circumventing that ban. The state saw it as an end-run around its own law—women getting abortions without ever setting foot in Louisiana, without the state being able to enforce its restrictions.
And the pharmaceutical companies—why did they care so much about this case that they rushed to the Supreme Court?
Because the appellate court's order threatened to upend their entire distribution system overnight. For years, they'd been shipping pills directly to patients' homes. Suddenly that was blocked. Clinics didn't know what they could prescribe. Pharmacies didn't know what they could dispense. It was chaos, and they needed clarity fast.
The numbers are striking—1.1 million medication abortions in a single year. Does that surprise you?
Not really. Once the pill became accessible by mail, it became the dominant method. It's safer than people assume, it works early in pregnancy, and it doesn't require a clinic visit. For someone in rural Montana or rural Louisiana, that's everything. It's the difference between access and no access.
Alito's dissent mentions that the pill's availability has "thwarted" Louisiana's efforts to ban abortion. That's a pretty stark admission of what's at stake.
It is. He's saying the real problem isn't the drug's safety or efficacy—it's that the drug works too well at getting around state bans. That's the actual fight. It's not about medicine. It's about whether states can enforce abortion restrictions when the pill can arrive by mail.
What happens next? The Supreme Court just bought time, right?
Exactly. They've preserved the status quo while the FDA does its safety review and while the lower courts continue litigating. But this isn't settled. The Trump administration is pushing that review forward. Eventually, the courts will have to decide whether the FDA's 2023 policy can stand. And that decision will ripple across every state.